Biomarkers of response to preoperative chemoradiation in esophageal cancers.
To identify a panel of biomarkers that predicts response of esophageal cancers to preoperative chemoradiation, our group profiled the gene expression of pretreatment cancer biopsies from patients with esophageal cancer. Six (32%) of these patients had pathologic complete response. All cancers except one that achieved pathologic complete response (83%) clustered in one molecular type (type I), while cancers that achieved less than pathologic complete response with one exception clustered in another molecular type (type II). Activated NF-kappaB was significantly associated with aggressive pathology. These data indicate that expression analysis of a limited set of biomarkers selected from the list of genes that were differentially regulated between the two subtypes can increase predictive power, and suggest that esophageal cancer with activated NF-kappaB may result in poor treatment outcome.
Luthra
Rajyalakshmi
R
Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USA. rluthra@mdanderson.org
Luthra
Madan G
MG
Izzo
Julie
J
Wu
Tsung-Teh
TT
Lopez-Alvarez
Enrique
E
Malhotra
Usha
U
Choi
In Seon
IS
Zhang
Li
L
Ajani
Jaffer A
JA
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000532:radiotherapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000532:radiotherapy; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D011878:Radiotherapy
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor